M.ChazouillresO.DrenthJ
Tirzepatide is administered as a once-weekly subcutaneous injection, with doses ranging from 2.5 mg to 15 mg depending on therapeutic indication and individual tolerance
Activation of these membrane receptors triggers downstream changes in mitogen-activated protein kinase (MAPK) and phosphatidyl-inositol-3-kinase/AKT (PI3K/AKT) pathways, ultimately influencing gene transcription 61,62
doi: 10.3389/fnut.2024.1398059 Received 08 March 2024 Accepted 12 April 2024 Published 29 April 2024 Volume 11 - 2024 Edited by Jorge Carriel Mancilla, Catholic University of Santiago de Guayaquil, Ecuador Reviewed by Ludwig Roberto lvarez Crdova, Catholic University of Santiago de Guayaquil, Ecuador Janeth Castano Jimenez, Indiana University Bloomington, United States Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2024 Tamayo-Trujillo, Ruiz-Pozo, Cadena-Ullauri, Guevara-Ramrez, Paz-Cruz, Zambrano-Villacres, Simancas-Racines and Zambrano
doi: 10.3389/fmed.2018.00124 158 OkumuraRTakedaK